Xofluza (Baloxavir Marboxil) Patent Expiration, LOE Window & CMS Spending

Xofluza (Baloxavir Marboxil) by Roche / Genentech: FDA Orange Book core substance LOE 2037-08-09 (last listed 2039-10-09), 1 AB generics, $3.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRoche / Genentech
FDA Application & PathwayN210854 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2037-08-09
Last Listed Patent or Exclusivity Date2039-10-09
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$3.5M
2024 Medicare Part D Spend$1.2M
2024 Medicaid Spend$2.3M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.